Related Experiment Videos
Pemetrexed and malignant pleural mesothelioma.
1Dipartimento di Oncologia ed Ematologia, Unità Operativa di Oncologia Medica, Azienda USl, Ravenna, Italy.
Summary
Malignant Pleural Mesothelioma (MPM) treatment remains challenging. New antifolate drug Pemetrexed shows promise, alone or with platinum compounds, in clinical trials for MPM patients.
Area of Science:
- Oncology
- Medical Chemistry
Background:
- Malignant Pleural Mesothelioma (MPM) presents significant treatment challenges.
- Limited surgical options and dismal chemotherapy outcomes necessitate novel therapeutic approaches.
Purpose of the Study:
- To report principal clinical experiences with Pemetrexed in Malignant Pleural Mesothelioma (MPM).
- To evaluate Pemetrexed efficacy alone and in combination with other agents, particularly platinum derivatives.
Main Methods:
- Review of clinical data from an Italian study involving 1114 MPM cases over 30 months.
- Analysis of treatment outcomes for patients receiving Pemetrexed-based regimens.
Main Results:
- Pemetrexed demonstrates particular activity in MPM, a challenging solid tumor.
- Combination therapies, especially with platinum compounds, are being investigated.
Conclusions:
- Pemetrexed represents a promising therapeutic option for Malignant Pleural Mesothelioma.
- Further external review of responsive patients is pending to finalize definitive results.